Endogenous adenosine inhibits P-selectin-dependent formation of coronary thromboemboli during hypoperfusion in dogs.
The activation of platelets and the formation of neutrophil- platelet conjugates may lead to the development of thromboemboli. We studied whether blockade of adenosine receptors during coronary hypoperfusion may cause thromboemboli via P-selectin-dependent mechanisms in 30 open-chest dogs. When coronary blood flow was reduced to 20% of the control, it was stable at low levels with increases in adenosine levels. When 8-p-sulfophenyltheophylline, an adenosine receptor antagonist, was infused during coronary hypoperfusion, coronary blood flow decreased gradually and approached almost zero 20 min after its administration. Histological examination revealed thromboemboli in the small coronary vessels. During hypoperfusion in the presence of 8-p-sulfophenyltheophylline, the mAb against P-selectin attenuated both the reduction in coronary blood flow and the formation of thromboemboli, and improved contractile and metabolic dysfunction of the myocardium. Flow cytometric analysis indicated that the expression of P-selectin on platelet and neutrophil-platelet adhesion were increased during coronary hypoperfusion, and that both were further augmented by 8-p-sulfophenyltheophylline. Immunohistochemical examination showed no staining of P-selectin in the ischemic myocardium. Adenosine inhibited the thrombin-induced expression of P-selectin on platelet and neutrophil- platelet adhesion via adenosine A2 receptors. Adenosine appears to inhibit the formation of thromboemboli during coronary hypoperfusion by suppressing the expression of P-selectin on platelets and neutrophil-platelet adhesion.
Minamino
T
T
The First Department of Medicine, Osaka University School of Medicine, Suita, Osaka 565, Japan.
Kitakaze
M
M
Asanuma
H
H
Tomiyama
Y
Y
Shiraga
M
M
Sato
H
H
Ueda
Y
Y
Funaya
H
H
Kuzuya
T
T
Matsuzawa
Y
Y
Hori
M
M
D000241:Adenosine / Q000502:physiology*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology; D002448:Cell Adhesion / Q000502:physiology; D003326:Coronary Circulation / Q000187:drug effects; D003328:Coronary Thrombosis / Q000209:etiology* / Q000473:pathology / Q000517:prevention & control*; D004285:Dogs; D005260:Female; D008297:Male; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology; D019007:P-Selectin / Q000502:physiology*; D010973:Platelet Adhesiveness / Q000187:drug effects / Q000502:physiology; D058915:Purinergic P1 Receptor Antagonists; D013806:Theophylline / Q000031:analogs & derivatives / Q000494:pharmacology; D013923:Thromboembolism / Q000209:etiology* / Q000473:pathology / Q000517:prevention & control*
D000911:Antibodies, Monoclonal; D019007:P-Selectin; D058915:Purinergic P1 Receptor Antagonists; C031433:8-(4-sulfophenyl)theophylline; D013806:Theophylline; D000241:Adenosine